Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lawrence Long"'
Autor:
Cornelius Nattey, Peter Nyasulu, Denise Evans, Elisabet Lönnermark, Lawrence Long, Nozipho Musakwa, Jacob Bor
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 1, p e0245427 (2021)
PLoS ONE, Vol 16, Iss 1, p e0245427 (2021)
Background Young people face many barriers to accessing appropriate health care services including screening for HIV and tuberculosis (TB). The study aimed to identify perceived barriers to the uptake of health services among young adults entering th
Autor:
Lawrence Long, Craig van Rensburg, Rebecca Berhanu, Denise Evans, Kamban Hirasen, Sydney Rosen
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 6, p e0217820 (2019)
PLoS ONE, Vol 14, Iss 6, p e0217820 (2019)
BackgroundDrug resistant-tuberculosis is a growing burden on the South African health care budget. In response the National Department of Health implemented two important strategies in 2011; universal access to drug-sensitivity testing for rifampicin
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 2, p e0148546 (2016)
PLoS ONE, Vol 11, Iss 2, p e0148546 (2016)
Background While most HIV care is provided on an outpatient basis, hospitals continue to treat serious HIV-related admissions, which is relatively resource-intensive and expensive. This study reports the primary reasons for HIV-related admission at a
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 8, p e71719 (2013)
PLoS ONE, Vol 8, Iss 8, p e71719 (2013)
Introduction Recent WHO guidelines for resource-limited settings recommend tenofovir in first-line antiretroviral therapy (ART) yet there are suggestions that patients receiving nevirapine with tenofovir have worse outcomes than those receiving efavi
Autor:
Sydney Rosen, Bruce A. Larson, Buyiswa Ndibongo, Matthew P. Fox, Lawrence Long, Kathryn Schnippel
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 4, p e35444 (2012)
PLoS ONE, Vol 7, Iss 4, p e35444 (2012)
Integrating POC CD4 testing technologies into HIV counseling and testing (HCT) programs may improve post-HIV testing linkage to care and treatment. As evaluations of these technologies in program settings continue, estimates of the costs of POC CD4 t